From labn.org
0 1
North America’s leading manufacturer of outsourced nutritional bars and functional powders ranks in top 15 percent of over 130,000 companies ANAHEIM, Calif., Nov. 20, 2024 /PRNewswire/ — Nellson Nutraceutical LLC, North America’s only full-service bar [...]
on Thu, 10PM
From labn.org
0 1
Amgen taps Stanford’s Howard Chang to take CSO reins from Jay Bradner gmasson Wed, 11/20/2024 – 16:35 Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
on Thu, 10AM
From labn.org
0 1
LOS ANGELES, Nov. 19, 2024 /PRNewswire/ — The National Hispanic Health Foundation (NHHF) is proud to announce the awarding of 18 new scholarships with the support of the United Health Foundation (up to $20,000) to [...]
on Wed, 10PM
From labn.org
0 1
RANCHO CUCAMONGA, Calif., Nov. 19, 2024 /PRNewswire/ — The nomination window for the 2025 Living the Mission Awards, presented by Inland Empire Health Plan (IEHP), is now open. Regional providers, community partner organizations, and entities [...]
on Wed, 10PM
From labn.org
0 1
BREA, Calif., Nov. 19, 2024 /PRNewswire/ — Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the company will participate in a fireside chat at the Evercore HealthCONx Conference on Tuesday, December 3, 2024 from [...]
on Wed, 9PM
From labn.org
0 1
TORRANCE, Calif., Nov. 19, 2024 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of [...]
on Wed, 9PM
From labn.org
0 0
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock [...]
on Nov 8
From labn.org
0 0
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives [...]
on Nov 7
From labn.org
0 0
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ — Dr. Scott McMahon of Whole World Health Care is happy to announce the launch of the MEDICINE AND MIRACLES podcast during the month of October, recognized as Health [...]
on Oct 31
From labn.org
0 0
Wholly owned first-in-class program anticipated to enter clinical trials in first half of 2025 THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has [...]
on Oct 31
From labn.org
0 0
COSTA MESA, Calif., Oct. 23, 2024 /PRNewswire/ — The following statement is being issued by Simpluris, Inc., court-appointed settlement administrator, regarding the proposed settlement in Wang, et al., v. Ampio Pharmaceuticals, Inc., et al., Case [...]
on Oct 25
From labn.org
0 0
Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron’s blockbuster Eylea, following an appeals court decision that ruled against competitor Regeneron. “We look forward to bringing Pavblu to patients as quickly [...]
on Oct 23
From labn.org
0 0
LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that Dr. Robert N. Weinreb, MD, [...]
on Oct 18
From labn.org
Bright Uro adds two industry pioneers to its Board of Directors - Los Angeles Biotechnology Network
0 0
Martha Goldberg Aronson and Dr. Sanford Siegel to provide leadership and guidance for upcoming product launch IRVINE, Calif., Oct. 17, 2024 /PRNewswire/ — Bright Uro, a medical device company with a mission to transform care [...]
on Oct 18
From labn.org
FDA delays decision on Amgen’s Lumakras in colorectal cancer - Los Angeles Biotechnology Network
0 0
The FDA has pushed back its decision deadline to move Amgen’s KRAS inhibitor Lumakras into metastatic colorectal cancer to January, the company told Endpoints News. The regulator was supposed to decide Thursday whether to approve [...]
on Oct 18
From labn.org
0 0
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life [...]
on Oct 17
From labn.org
0 0
PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to confirm that it will be presenting data on its [...]
on Oct 8
From labn.org
0 0
Jim Collins, the famed MIT professor and a godfather of the synthetic biology field, describes Felix Wong as one of the most talented researchers to come out of his lab in recent years. Wong, 31, [...]
on Oct 3
From labn.org
0 0
The biggest drug driving Sanofi’s and Regeneron’s businesses is about to get a bit bigger. On Friday, the FDA approved Dupixent as an add-on to typical inhaled medicines for patients with inadequately controlled COPD, or [...]
on Sep 28
From labn.org
0 0
Supplement Industry Leader Introduces Multi+™ Multivitamins for Women, Men, and Mood SHERMAN OAKS, Calif., Sept. 25, 2024 /PRNewswire/ — With consumers seeking enhanced benefits such as energy, digestive and beauty in their daily supplements, Jarrow [...]
on Sep 26
From labn.org
STAT+: Regeneron’s Eylea biosimilar fight heats up - Los Angeles Biotechnology Network
0 0
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock. Click here to view original post Click [...]
on Sep 25
From labn.org
0 0
Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. The biotech said the changes reflect the comorbidities of people with acute on-chronic liver [...]
on Sep 22
From labn.org
0 0
Just hours after the US Federal Reserve announced the first interest rate cut in four years, respiratory biotech Upstream Bio revealed plans for a public listing. The Boston-area biotech unveiled its investor prospectus on Wednesday [...]
on Sep 20
From labn.org
0 0
Viridian Therapeutics on Tuesday reported topline Phase 3 data for its rare autoimmune disease drug veligrotug as it aims to compete with Amgen and Horizon’s Tepezza. Veligrotug hit on all primary and secondary endpoints in [...]
on Sep 11
From labn.org
0 0
Ken Song knows how to step on the gas pedal. His new company, called Candid Therapeutics, emerged from stealth on Monday morning with more than $370 million to its name and two clinical-stage T cell [...]
on Sep 10
From labn.org
0 0
On Sunday evening, abstracts from the European Society for Medical Oncology were released. While some of oncology’s most exciting recent data were reported a week before at a separate conference, ESMO still has late-breaking results [...]
on Sep 10
From labn.org
BioMarin to lay off over 200 employees - Los Angeles Biotechnology Network
0 1
Amid a major corporate shakeout, BioMarin Pharmaceutical intends to lay off over 200 staff, according to a regulatory filing made Wednesday by the rare disease drug developer. In the notice, Biomarin said it has “committed [...]
on Sep 4
From labn.org
0 1
Adaptin Bio is launching with plans to bring a bispecific T cell engager for glioblastoma, a deadly form of brain cancer, into the clinic. The company received FDA clearance to start its clinical trial, which [...]
on Sep 4
From labn.org
0 1
BioMarin’s decision to scale back its gene therapy ambitions will result in about 225 employees losing their jobs, the biotech disclosed late Wednesday. The layoffs, which are tied to “organizational redesign efforts,” are expected to [...]
on Aug 30
From labn.org
0 1
Acquisition of Mumbai-based generic pharmaceutical business led by Platinum’s Asia investment team LOS ANGELES and MUMBAI, India, Aug. 29, 2024 /PRNewswire/ — Platinum Equity announced today the acquisition of a controlling stake in Inventia Healthcare [...]
on Aug 30
From labn.org
Novartis seeks to expand Leqvio into heart disease prevention - Los Angeles Biotechnology Network
0 0
Novartis announced Wednesday that Leqvio lowered bad cholesterol levels, compared with a placebo or the cholesterol-lowering drug ezetimibe, in patients at low-to-moderate risk of developing atherosclerotic heart disease. In the Phase 3 V-Mono study, 350 [...]
on Aug 29
From labn.org
0 0
Vaderis Therapeutics announced Tuesday morning that its lead drug candidate, an AKT inhibitor, helped reduce nosebleeds in people with hereditary hemorrhagic telangiectasia, a genetic disorder in which the blood vessels don’t form properly. It’s the [...]
on Aug 28
From labn.org
0 0
Another autoimmune biotech emerged on Tuesday morning with a $100 million Series A. Navigator Medicines launched with a license to a Phase 1 bispecific antibody and a pipeline of other assets from Korea-based IMBiologics, which [...]
on Aug 28
From labn.org
0 0
Transformative donation will spur breakthrough discoveries and drive economic growth for the region LOS ANGELES, Aug. 27, 2024 /PRNewswire/ — UCLA has received a $120 million commitment from surgeon, inventor and philanthropist Dr. Gary Michelson [...]
on Aug 28
From labn.org
0 0
SANTA ANA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), today announced it received a standard notice (the “Notice”) on August 20, 2024 from the Listing Qualifications [...]
on Aug 24
From labn.org
Love A Wholistic Life Launches Nutritional Weight Loss Courses - Los Angeles Biotechnology Network
0 0
Premier Plant-Based Nutrition Program and Coaching Service Announces Sustainable Wellness Through Comprehensive Nutrition and Lifestyle Guidance LOS ANGELES, Aug. 22, 2024 /PRNewswire/ — Love a Wholistic Life, a premier nutrition and coaching service that gives [...]
on Aug 23
From labn.org
0 0
New Research Highlights Performance Gains with Technologically Advanced Training Tools GARDEN GROVE, Calif., Aug. 14, 2024 /PRNewswire/ — BodyKore, a leader in smart fitness solutions, is proud to announce the results of a recent scientific [...]
on Aug 16
From labn.org
0 0
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2024 and provided general business updates. Click here [...]
on Aug 16
From labn.org
0 1
THOUSAND OAKS, Calif.–(BUSINESS WIRE)—- $ATRA #CART–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, [...]
on Aug 14
From labn.org
0 1
Susan Altschuller → Bill Haney’s Dragonfly Therapeutics has brought aboard Susan Altschuller as CFO. Altschuller’s résumé includes other finance chief roles at Cerevel Therapeutics and ImmunoGen, which were both recently acquired by AbbVie. Earlier in her [...]
on Aug 10
From labn.org
0 0
Industry Leader Weighs in on Potential Implications for Mental Health Treatment Landscape LOS ANGELES, Aug. 8, 2024 /PRNewswire-PRWeb/ — As the mental health community awaits a potentially groundbreaking decision from the U.S. Food and Drug [...]
on Aug 10
From labn.org
0 0
Proposed Bill Estimated to Cost $250 Million in State Sales Tax Revenue and Up to 41,000 Jobs LOS ANGELES, Aug. 8, 2024 /PRNewswire/ — In a blow to California’s already strained budget deficit, Assembly Bill [...]
on Aug 9
From labn.org
0 0
Amgen’s Horizon deal is starting to pay off, as the biotech giant reported a 20% increase in revenue compared with a year prior. In total, Amgen reported sales of $8.4 billion, about $1 billion more [...]
on Aug 8
From labn.org
AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND - Los Angeles Biotechnology Network
0 0
THOUSAND OAKS, Calif., Aug. 2, 2024 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the third quarter of 2024. The dividend will be paid on [...]
on Aug 6
From labn.org
0 1
To transform compliance from a red tape burden to a real guardrail, medtech companies should adopt developer-first approaches like shift-left testing. Click here to view original post Click Here to Publish/Feature Your Company or Product [...]
on Jul 29
From labn.org
Biogennix Launches Agilon Surgical Matrix - Los Angeles Biotechnology Network
0 0
IRVINE, Calif.–(BUSINESS WIRE)– #agilon–Biogennix, an osteobiologics company specializing in innovative healing solutions for surgical procedures, has announced the launch of its new Agilon Surgical Matrix wound care product. Agilon Surgical Matrix is a wound care [...]
on Jul 26
From labn.org
Statement from Emily Robinson, Attorney for Alison Chao - Los Angeles Biotechnology Network
0 0
WESTLAKE VILLAGE, Calif., July 23, 2024 /PRNewswire/ — The following statement is from Emily Robinson, attorney for Alison Chao: “In May 2024, I was appointed as counsel for Alison Chao by the Superior Court of [...]
on Jul 24
From labn.org
0 0
A biotech startup trying to expand the limited palette that nature uses to make proteins has raised funds to test its creations in humans for the first time. The company, called GRO Biosciences, is based [...]
on Jul 21
From labn.org
0 0
Effective Immediately, Fitness International will assume operations of XSport Fitness’ 35 locations. IRVINE, Calif., July 16, 2024 /PRNewswire/ — Fitness International, LLC, operator of LA Fitness, Esporta Fitness, City Sports Club, and Club Studio brands, [...]
on Jul 17
From labn.org
0 0
CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other drugmakers for weight loss — through Phase 2b trials [...]
on Jul 17